Additive cardioprotection by ethanol and sevoflurane: are sarcolemmal K ATP channels also involved?
Pagel
Paul S
PS
D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004789:Enzyme Activation; D000431:Ethanol / Q000494:pharmacology* / Q000627:therapeutic use; D054086:KATP Channels / Q000187:drug effects* / Q000378:metabolism; D008738:Methyl Ethers / Q000494:pharmacology* / Q000627:therapeutic use; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D015221:Potassium Channels / Q000187:drug effects* / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D012508:Sarcolemma / Q000187:drug effects* / Q000378:metabolism; D000077149:Sevoflurane
D002316:Cardiotonic Agents; D054086:KATP Channels; D008738:Methyl Ethers; D015221:Potassium Channels; C117780:mitochondrial K(ATP) channel; D000077149:Sevoflurane; D000431:Ethanol; D011493:Protein Kinase C